Background: To report outcomes of proton therapy in head and neck adenoid cystic carcinoma.
INTRODUCTION
Adenoid cystic carcinoma (ACC) is an uncommon secretory gland tumor most often arising in salivary tissue in the head and neck. Its natural history is marked by a propensity for perineural tumor spread and both local recurrence and distant metastatic disease. Many patients have a history of slow indolent tumor growth with a prolonged clinical course, but those with lymphatic invasion, solid tumor histology, or high-grade transformation appear to have a more aggressive clinical course and reduced survival. 1, 2, 3 The incidence of ACC appears to be decreasing over time, and there is suggestion that survival is superior in women compared to men. 4 Surgical resection and postoperative radiotherapy are the standard of care, while systemic therapy has been of little utility. 5 Patients with advanced tumor stage disease 6, 7, 8 and involvement of the skull base have poor outcomes, 9,10 as disease cannot usually be surgically extirpated and the lower radiation tolerance of closely adjacent critical normal structures such as the optic apparatus, brainstem, and temporal lobes can preclude delivery of radical doses of radiotherapy. In these patients, local disease control is of special importance, given the profound sequelae of disease progression at the skull base.
Given the suboptimal results of x-ray based radiation therapy for patients with unresectable or gross residual disease or those with skull base involvement, 6,9,11,12 ,13 dose intensification has been explored. Prior studies have suggested a dose response relationship for ACC, 14, 15, 16 where higher doses seem to be associated with improved and durable local tumor control. Neutron therapy has been used to provide a biologically more potent dose of radiation therapy for patients with unresectable salivary gland tumors: although the 5-year locoregional control rate for patients with ACC and skull base involvement was a disappointing 15-23%, 11, 12 though improved with addition of a gamma knife radiosurgery boost. 17 Proton therapy is a modality of radiation therapy with a biologic effect normalized to be identical to megavoltage Xrays, but with superior dose localization, facilitating dose-escalation while respecting the dose constraints of surrounding normal structures. 18 We report initial clinical outcomes of proton therapy at our institution for head and neck ACC.
MATERIALS AND METHODS
Institutional review board approval was obtained for this retrospective review. Twenty-seven consecutive patients were treated at the Indiana University Health Proton Therapy Center between June 2004 and April 2012 for head and neck adenoid cystic cancer. One patient, who was reirradiated with palliative intent (30 Gy in 10 fractions), was excluded from analysis. The remaining 26 patients were treated with curative intent: 19 (73%) were treated for their initial disease course 4 and 7 (27%) were treated for recurrent disease. Twenty patients (77%) were treated after surgery, and 18 of these (90%) had positive margins or gross residual disease. The remaining 6 patients (23%) were treated after biopsy alone.
Skull base involvement was defined as tumor involving the infratemporal fossa, clivus, foramen ovale, foramen rotundum, cavernous sinus, sphenoid sinus, orbit, or intracranial tumor extension. In the subset of 19 patients treated in their initial disease presentation, 14 had skull base involvement and none had metastatic disease at presentation. In the subset of 7 patients treated for recurrent disease, 6 had received prior head and neck radiation, 6 had skull base involvement, and 3 had known distant metastatic pulmonary disease, but received aggressive local therapy due to the clinically indolent nature of their distant metastases and the importance of obtaining local control. Table 1 lists patient characteristics. Half the patients were treated by the senior author.
Included in the analysis are two patients who received some component of photon therapy. One patient was referred for a proton therapy boost after initial delivery of 61.2 Gy of intensity modulated photon radiation therapy (IMRT) at an outside institution. One patient received 14.4 Gy of IMRT before beginning proton therapy due to her weight initially being in excess of our table tolerance. The remaining patients were treated exclusively with proton therapy.
Proton treatment planning involved creation of custom immobilization devices including a thermoplastic face mask, alpha cradle body mold, and acquisition of a non-contrast treatment planning CT scan with 1 mm slice thickness.
Preoperative and postoperative imaging was coregistered to delineate the initial extent of tumor, areas of residual disease, and postoperative anatomy. The target volume covered the primary tumor bed and course of the initial tumor and included coverage of the skull base, tracking any involved cranial nerve through the skull base foramina to the surface of the brainstem. Ipsilateral cervical lymphatics were irradiated in the 1 node positive patient. Limited regional nodal irradiation was delivered electively in 7 other patients per the preference of one of the treating physicians.
Proton treatment planning was three-dimensional conformal radiotherapy using uniform scanning beam delivery, which delivers a uniform spread out Bragg peak across each field. 19 The choice of beam angles and number of beams varied by the extent and complexity of each individual patient's tumor. Brass apertures were fabricated to define the shape of each field and conform to the lateral extent of the target, with Lucite range compensators milled to shape the distal end of the proton beam, achieving distal conformality to the target. Treatment optimization involved multiple iterative adjustments in individual field shape and design to achieve the desired target coverage and normal tissue sparing. Our institutional practice is to use a 2 mm expansion on clinical target volumes to create a planning target volume, which accounts for patient setup uncertainties. Individual beam parameters including compensator smearing were selected with consideration of the 5 surrounding tissue heterogeneities and potential uncertainties inherent in each unique beam path. Range uncertainty is dependent on depth or energy but generally 2-4 mm in the head and neck. Details of our proton beam delivery system have been previously published. 20 Daily kilovoltage orthogonal X-ray images were taken to align the patient prior to treatment of each field, with adjustments made on a robotic patient positioner with six degrees of freedom to achieve near stereotactic treatment alignment, verified by a physician prior to treatment delivery. 21 Patients were treated with once daily fractionation of 1.8 -2 Gy (RBE). Proton dose is expressed in Gy (RBE) with a relative biologic effectiveness of 1.1 compared to megavoltage X-ray therapy. A strategy of high dose radiotherapy was pursued per institutional approach, based on the prior published experience with high-dose proton radiotherapy in this disease. 22 The total dose administered was 75.6 Gy (RBE) for gross disease and 66 -70.2 Gy (RBE) for negative margins.
For those with positive margins, the dose was 70.2 -72 Gy (RBE), attenuated to 66.6 Gy (RBE) in 1 patient due to proximity to the optic nerve in a patient with a single sighted eye, and to 68. confidence intervals (CI) are presented. The log-rank test was used to perform univariate analysis of patient and disease characteristics. Variables with a p value < 0.2 on univariate analysis were selected for inclusion in a Cox multivariate regression analysis using block entry method to explore association with local control and overall survival.
Information on acute and late toxicity was retrospectively gathered from weekly treatment status notes, the treatment completion summary, follow-up notes, and correspondence from follow-up with other physicians and graded according to the Common Terminology Criteria for Adverse Events (version 4.0) of the National Cancer Institute.
RESULTS
The median follow-up on all patients was 25 months (range 7 -54 months) and 27 months in patients that are alive.
The 2-year estimate of OS was 82% (95% CI 66-98%). The 2-year estimate of LC was 92% (95% CI 82-100% The 2-year OS for those without skull base involvement was 100% compared to 77% (95% CI 58-97%) for those with skull base disease (Figure 4 , p=0.17).
The 2-year LC for patients irradiated after biopsy only (n=6) was 100% compared to 90% (95% CI 77-100%) for patients treated with surgery and postoperative radiation (p=0.97). The 2-year LC for patients treated with macroscopic residual disease with or without surgical resection (n=12) was 93% (95% CI 79-100%) compared to 92% (95% CI 76-100%)
for patients treated without gross residual disease (p=0.64).
Fourteen patients with skull base involvement were treated with proton therapy in their initial disease presentation.
Among these patients, the median follow-up time was 27 months (range 11-50 months). The 2-year estimates of LC, OS and DM were 93%, 91%, and 32% respectively ( Figure 5 ).
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Among the 7 patients with recurrent disease, 6 had received one or more courses of prior radiation therapy. The median follow-up for these 7 patients was 24 months (range 7-43 months). The 2-year estimates of LC, OS and DM were 86%, 57%, and 25% respectively.
Pattern of Failure Analysis
Isolated local recurrences occurred in two patients at 3 months and 45 months after treatment, respectively. Both tumors originated in the ethmoid sinus, involved the base of skull, and both patients had gross residual disease at the time of radiation. One patient had been treated for recurrent, previously irradiated disease and progressed within the 75.6 Gy (RBE) dose region. The second patient was treated for their initial disease presentation, receiving radiation only to the postoperative volume of residual tumor, and developed recurrent tumor within the primary tumor bed, which, for unclear reasons, was excluded from the radiation treatment volume. It was noted that in this patient, the preoperative MRI had not been coregistered to aid in delineation of the initial disease extent. One additional patient with a nasal cavity primary developed an orbital apex recurrence accompanied by bone metastases 2 months after radiation therapy, and was noted to have suboptimal coverage of the foramen rotundum.
Treatment Toxicity
Acute toxicity included transient radiation dermatitis of maximum grade II in 16 patients, lateralized mucositis of maximum grade II in 7 patients, and 2 patients with grade II serous otitis. Of the two patients treated for orbital tumors with an intact eye, one developed an acute grade III keratitis requiring treatment to be held temporarily for resolution. One other patient with a sinonasal primary had a brief treatment interruption for initiation of treatment of a nasal cavity methicillinresistant staphylococcus aureus infection. All patients completed the prescribed course of radiation.
Late toxicity of grade 0 or 1 was seen in 17 patients, grade 2 in 5 patients, grade 3 in 2 patients, grade 4 in 1 patient, and grade 5 in 1 patient. The grade 3 toxicities included mandibular osteoradionecrosis in one patient treated for initial disease in whom 9 cm 3 of the mandible (11.6% relative volume) received a dose of 70 Gy (RBE) or higher, with a maximum mandible dose of 82.9 Gy (RBE). The mandible had not been contoured by the treating physician, which may explain why alternate beam arrangements were not used to keep the mandible at acceptable dose constraints. Hyperbaric oxygen therapy was employed with improvement. A second patient who previously received 50.4 Gy of photon therapy was reirradiated for recurrent parotid disease six years later to 72 Gy (RBE) and 27 months later developed grade 3 otologic toxicity requiring tympanic membrane reconstruction. The grade 4 toxicity was anticipated unilateral vision loss in a patient who was irradiated for an orbital tumor that directly involved the optic nerve and consented to the expectation of vision loss. The 8 single case of late grade 5 toxicity developed in a patient with a history of an extensive nasopharyngeal adenoid cystic carcinoma previously irradiated with 54 Gy of IMRT and who later received 3 Gamma Knife radiosurgery treatments to different areas of recurrent head and neck disease over a 6 year timeframe. None of the patient's prior radiation treatment plans had been archived in digital format, so it was impossible to accurately reconstruct the lifetime composite dose distribution. Two years after the most recent prior radiation, in the absence of distant metastatic disease, the patient was reirradiated to 75.6 Gy (RBE) to progressive painful gross recurrent disease in the infratemporal fossa and frontal sinus. The patient had radiographic and clinical regression of disease and improvement in pain, but six months later developed a cerebrospinal fluid leak and meningitis, and subsequently died.
DISCUSSION
Pommier and colleagues have reported results of high-dose proton therapy for patients with skull base ACC, finding a 5-year local control of 93% (100% at 2 years) in 23 patients who had received a median dose of 75.9 Gy (RBE), mostly treated with an hyperfractionated accelerated concomitant boost technique. 22 These results are encouraging in a population of patients with advanced, complex disease, and support a strategy of dose escalation, which was accomplished with acceptable toxicity using proton therapy. All of these patients received some component of photon therapy (median proton component was 60% of the dose), due in part to the limited clinical availability of the former Harvard Cyclotron Laboratory, in contrast to our own experience, which used once daily fractionation and exclusively proton therapy in all but two patients. Among our subset of 14 patients with base of skull involvement treated for initial disease presentation, the 2-year local control was 100% after a median dose of 72 Gy (RBE) in once daily fractionation.
A review of the literature on ACC which reports results by base of skull involvement or T stage (Table 2) negative margins. 15 However, in patients with earlier stage disease in more favorable sites where there is less rationale for dose escalation, proton therapy may offer an advantage in mitigating toxicities of therapy. Figure 6 illustrates a clinical example where proton therapy was used to eliminate oral cavity irradiation and preserve salivary gland function in a patient with a buccal mucosa ACC.
Patients treated more intensively, either with high-dose photon 6 or proton 22 therapy, or neutron therapy with radiosurgical boost, 17 appear to have improved disease control compared to older series of non-operative management with lower dose photon therapy, raising the possibility of using more conformal radiotherapy techniques for non-surgical management in patients for whom radical resection would be excessively morbid. The comparatively poor results seen in series of patients treated with radiation therapy alone for advanced disease may reflect delivery of insufficient dose of radiotherapy for gross disease, often complicated by proximity of unresectable disease to critical normal structures that have a lower tolerance dose to radiotherapy. In our series, 6 patients were treated after biopsy alone, and 14 with macroscopic residual disease, with results that did not appear inferior to those treated postoperatively for microscopic residual disease.
Similarly, in the series by Pommier and colleagues, local disease control was maintained at both 5 and 10 years among all 11 patients treated for skull base disease with high-dose proton therapy after biopsy only.
Our experience with high dose proton therapy reflects a short median follow-up time, and more mature follow-up is desired in this disease with a long natural history. The data for high dose radiotherapy is retrospective and has not been rigorously compared against standard dose radiotherapy, which limits the conclusions which can be drawn regarding the role of dose escalation in obtaining local control.
Late treatment toxicity in patients treated for their initial disease course was modest with 1 patient developing grade 3 toxicity which is not surprising given the large volume of mandible treated to a high dose, and 1 patient with grade 4 vision loss which was anticipated in treatment of an orbital tumor involving the optic nerve in a patient who otherwise would have required enucleation. Additional late toxicity was seen in the smaller subset of patients treated for recurrent disease, including one death due to cerebrospinal fluid leak and meningitis in a heavily pretreated patient. Given the small numbers involved, there was no statistically significant difference in toxicity among the treatment naïve and previously irradiated cohorts.
Our experience with 7 patients with recurrent disease, 6 of whom had previously been irradiated, demonstrated a surprisingly good 2-year LC of 86%. In this subset of patients with particularly challenging disease complicated by one or more prior courses of radiation therapy, high-dose proton therapy was pursued in an effort to obtain control of skull base disease causing or threatening significant clinical deficits. In one patient who had undergone prior IMRT and 3 radiosurgery procedures, reirradiation may have contributed to subsequent cerebrospinal fluid leak, meningitis, and death, which underscores the potential for significant toxicity with reirradiation. The safety and efficacy of reirradiation in this complex cohort of patients cannot be evaluated from this small subset. Comprehensive reviews of the role of reirradiation in head and neck cancer have been published. 23 Additional limitations of this study include its retrospective nature, the relatively small number of patients, and the short median follow-up time, with longer follow-up necessary to assess the durability of local disease control. Our study benefits from a relatively uniform treatment approach to these patients over the study period. The importance of careful treatment planning and the complexity of care involved in treatment of patients with skull base disease is underscored by the pattern of failure analysis which revealed that 2/3 of the local failures may have been prevented by changes in treatment volume.
While optimizing local control and reducing toxicity of local therapy remains an important goal of future research, the insidious course of adenoid cystic carcinoma and the high propensity for distant metastatic disease 24 underscore the importance of continued efforts in evaluating the role of systemic therapies and developing novel agents with activity against ACC.
CONCLUSIONS
In our initial clinical experience among patients with mostly advanced stage head and neck adenoid cystic carcinoma, high-dose proton therapy provides encouraging preliminary local control. Longer follow-up is needed to gauge the durability of disease control and to monitor for late toxicities of therapy. Careful treatment planning is essential to optimize outcomes. 
